The company has raised $38 million in venture capital funding since it was founded in 2019.
Click here to view original post
News
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2024 and recent business highlights. “We continue to make strong progress on our […]
News
Groundbreaking Study by CELLg8 Reveals Liposomal Delivery Successfully Boosts Intracellular NAD+ Levels in Humans
FORT COLLINS, Colo., April 23, 2026 /PRNewswire/ — A newly published study in the Journal of Applied Natural Medicine has announced a significant breakthrough in metabolic health. The research, titled “Increased Intracellular NAD+ Levels via […]
News
Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced today the Seattle Children’s activation of the Phase 1 ENLIGHTen clinical trial in […]
